Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient

Dow Jones09-06

By Josh Beckerman

Shares of Hoth Therapeutics rose after it reported favorable results for the first-of-its-kind human patient treatment of skin toxicities associated with epidermal growth factor receptor inhibitors with its HT-001 drug.

The stock was up 49% to $1.06 Thursday, and is down about 26% this year. Volume was more than 149 million shares, compared with a 65-day average of 776,168.

The company said a cancer patient experienced significant improvement in symptoms a week after initiating HT-001 therapy. "Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days," the company said. Over the following three weeks, no new lesions developed, Hoth said.

Hoth also said it received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

September 05, 2024 14:15 ET (18:15 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2465793575?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-09-06 02:15","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2465793575","market":"hk","top_or_hot":-1,"title":"Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre>\n \n</pre>\n<p>\n  By Josh Beckerman \n</p>\n<pre>\n \n</pre>\n<p>\n  Shares of <a href=\"https://laohu8.com/S/HOTH\">Hoth Therapeutics</a> rose after it reported favorable results for the first-of-its-kind human patient treatment of skin toxicities associated with epidermal growth factor receptor inhibitors with its HT-001 drug. \n</p>\n<p>\n  The stock was up 49% to $1.06 Thursday, and is down about 26% this year. Volume was more than 149 million shares, compared with a 65-day average of 776,168. \n</p>\n<p>\n  The company said a cancer patient experienced significant improvement in symptoms a week after initiating HT-001 therapy. \"Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days,\" the company said. Over the following three weeks, no new lesions developed, Hoth said. \n</p>\n<p>\n  Hoth also said it received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001. \n</p>\n<pre>\n \n</pre>\n<p>\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n</p>\n<pre>\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  September 05, 2024 14:15 ET (18:15 GMT)\n</p>\n<p>\n  Copyright (c) 2024 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHoth Therapeutics Reports Favorable Results for First-of-Its-Kind HT-001 Treatment of a Patient\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-06 02:15 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>By Josh Beckerman \n\n\n \n\n\n  Shares of Hoth Therapeutics rose after it reported favorable results for the first-of-its-kind human patient treatment of skin toxicities associated with epidermal growth ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1167","symbol_name":"电子制造服务","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2465793575","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2465793575","pubTimestamp":1725560100,"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares of Hoth Therapeutics rose after it reported favorable results for the first-of-its-kind human patient treatment of skin toxicities associated with epidermal growth factor receptor inhibitors with its HT-001 drug.The stock was up 49% to $1.06 Thursday, and is down about 26% this year. Volume was more than 149 million shares, compared with a 65-day average of 776,168.The company said a cancer patient experienced significant improvement in symptoms a week after initiating HT-001 therapy. \"Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days,\" the company said. Over the following three weeks, no new lesions developed, Hoth said.Hoth also said it received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1167":"电子制造服务","BK4218":"酒店及度假村房地产信托","HT":"HT基金","HOTH":"Hoth Therapeutics","BK4181":"酒店及度假村房地产投资信托","01611":"新火科技控股","BK4007":"制药"},"translate_title":"Hoth Therapeutics报告了首个HT-001治疗患者的良好结果","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01611":1,"HOTH":1,"HT":1},"content_text":"By Josh Beckerman \n\n\n \n\n\n  Shares of Hoth Therapeutics rose after it reported favorable results for the first-of-its-kind human patient treatment of skin toxicities associated with epidermal growth factor receptor inhibitors with its HT-001 drug. \n\n\n  The stock was up 49% to $1.06 Thursday, and is down about 26% this year. Volume was more than 149 million shares, compared with a 65-day average of 776,168. \n\n\n  The company said a cancer patient experienced significant improvement in symptoms a week after initiating HT-001 therapy. \"Due to the swift resolution of lesions and the alleviation of discomfort, the patient was able to discontinue the treatment after just seven days,\" the company said. Over the following three weeks, no new lesions developed, Hoth said. \n\n\n  Hoth also said it received Institutional Review Board approval from the Montefiore Medical Center and the Dana-Farber Cancer Institute to proceed with its First-in-Human Phase 2a clinical trial of HT-001. \n\n\n \n\n\n  Write to Josh Beckerman at josh.beckerman@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 05, 2024 14:15 ET (18:15 GMT)\n\n\n  Copyright (c) 2024 Dow Jones & Company, Inc.","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"Product Release","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2465793575"}